Comparative Pharmacology
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIC CHLORIDE versus MVC PLUS.
CUPRIC CHLORIDE vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Copper is an essential trace element that serves as a cofactor for various enzymes, including cytochrome c oxidase (involved in mitochondrial respiration), superoxide dismutase (antioxidant defense), ceruloplasmin (iron metabolism), and lysyl oxidase (collagen cross-linking). It also participates in neurotransmitter synthesis and maintenance of vascular integrity.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
0.5 to 1.5 mg copper (0.14 to 0.42 mg/mL) IV daily as a supplement in TPN; typical adult dose: 0.4 mg copper/day IV.
10 mg orally once daily.
None Documented
None Documented
Terminal half-life is approximately 12-24 hours; clinically relevant for dosing intervals in parenteral nutrition.
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Primarily biliary (>80%) into feces; renal excretion accounts for <5% of total copper elimination under normal conditions.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Mineral Supplement
Multivitamin/Mineral Supplement